| Cancer regression in patients after transfer of genetically engineered lymphocytes RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ... Science 314 (5796), 126-129, 2006 | 4193 | 2006 |
| Cancer immunotherapy: moving beyond current vaccines SA Rosenberg, JC Yang, NP Restifo Nature medicine 10 (9), 909-915, 2004 | 3812 | 2004 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ... Science 298 (5594), 850-854, 2002 | 3768 | 2002 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy SA Rosenberg, JC Yang, RM Sherry, US Kammula, MS Hughes, ... Clinical cancer research 17 (13), 4550-4557, 2011 | 2683 | 2011 |
| Adoptive cell transfer as personalized immunotherapy for human cancer SA Rosenberg, NP Restifo Science 348 (6230), 62-68, 2015 | 2650 | 2015 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ... Nature medicine 4 (3), 321-327, 1998 | 2259 | 1998 |
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma ME Dudley, JR Wunderlich, JC Yang, RM Sherry, SL Topalian, NP Restifo, ... Journal of clinical oncology 23 (10), 2346-2357, 2005 | 2152 | 2005 |
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy SA Rosenberg, NP Restifo, JC Yang, RA Morgan, ME Dudley Nature Reviews Cancer 8 (4), 299-308, 2008 | 2143 | 2008 |
| A human memory T cell subset with stem cell–like properties L Gattinoni, E Lugli, Y Ji, Z Pos, CM Paulos, MF Quigley, JR Almeida, ... Nature medicine 17 (10), 1290-1297, 2011 | 2129 | 2011 |
| Adoptive immunotherapy for cancer: harnessing the T cell response NP Restifo, ME Dudley, SA Rosenberg Nature Reviews Immunology 12 (4), 269-281, 2012 | 2099 | 2012 |
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 PF Robbins, RA Morgan, SA Feldman, JC Yang, RM Sherry, ME Dudley, ... Journal of Clinical Oncology 29 (7), 917-924, 2011 | 1955 | 2011 |
| Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma GQ Phan, JC Yang, RM Sherry, P Hwu, SL Topalian, ... Proceedings of the National Academy of Sciences 100 (14), 8372-8377, 2003 | 1946 | 2003 |
| Adoptive immunotherapy for cancer: building on success L Gattinoni, DJ Powell Jr, SA Rosenberg, NP Restifo Nature Reviews Immunology 6 (5), 383-393, 2006 | 1945 | 2006 |
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen LA Johnson, RA Morgan, ME Dudley, L Cassard, JC Yang, MS Hughes, ... Blood, The Journal of the American Society of Hematology 114 (3), 535-546, 2009 | 1752 | 2009 |
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens ME Dudley, JC Yang, R Sherry, MS Hughes, R Royal, U Kammula, ... Journal of Clinical Oncology 26 (32), 5233-5239, 2008 | 1678 | 2008 |
| Natural selection of tumor variants in the generation of “tumor escape” phenotypes HT Khong, NP Restifo Nature immunology 3 (11), 999-1005, 2002 | 1474 | 2002 |
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy RA Morgan, N Chinnasamy, D Abate-Daga, A Gros, PF Robbins, Z Zheng, ... Journal of immunotherapy 36 (2), 133-151, 2013 | 1315 | 2013 |
| Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells L Gattinoni, SE Finkelstein, CA Klebanoff, PA Antony, DC Palmer, ... The Journal of experimental medicine 202 (7), 907-912, 2005 | 1234 | 2005 |
| T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis MR Parkhurst, JC Yang, RC Langan, ME Dudley, DAN Nathan, ... Molecular Therapy 19 (3), 620-626, 2011 | 1217 | 2011 |
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells L Gattinoni, CA Klebanoff, DC Palmer, C Wrzesinski, K Kerstann, Z Yu, ... The Journal of clinical investigation 115 (6), 1616-1626, 2005 | 1203 | 2005 |
Steven A RosenbergNCI在 nih.gov 的电子邮件经过验证